These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Stepanova M; Younossi ZM Clin Gastroenterol Hepatol; 2012 Jun; 10(6):646-50. PubMed ID: 22245962 [TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients. Mikolasevic I; Racki S; Zaputovic L; Lukenda V; Milic S; Orlic L Med Hypotheses; 2014 Feb; 82(2):205-8. PubMed ID: 24365277 [TBL] [Abstract][Full Text] [Related]
5. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
14. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019 [TBL] [Abstract][Full Text] [Related]
15. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J; Cusi K Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with nonalcoholic fatty liver. Rafiq N; Bai C; Fang Y; Srishord M; McCullough A; Gramlich T; Younossi ZM Clin Gastroenterol Hepatol; 2009 Feb; 7(2):234-8. PubMed ID: 19049831 [TBL] [Abstract][Full Text] [Related]
17. [Fatty liver and global cardiometabolic risk]. Szollár L Orv Hetil; 2010 Nov; 151(47):1946-50. PubMed ID: 21071306 [TBL] [Abstract][Full Text] [Related]
19. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197 [No Abstract] [Full Text] [Related]
20. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Ghouri N; Preiss D; Sattar N Hepatology; 2010 Sep; 52(3):1156-61. PubMed ID: 20658466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]